These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12798317)

  • 21. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
    Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells.
    Aboud-Pirak E; Lesur B; Rao KS; Baurain R; Trouet A; Schneider YJ
    Biochem Pharmacol; 1989 Feb; 38(4):641-8. PubMed ID: 2917019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclodextrin derivatives conjugated with aromatic moieties as pH-responsive drug carriers for anthracycline.
    Swiech O; Dutkiewicz P; Wójciuk K; Chmurski K; Kruszewski M; Bilewicz R
    J Phys Chem B; 2013 Oct; 117(43):13444-50. PubMed ID: 24079546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
    Taatjes DJ; Fenick DJ; Koch TH
    J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploiting anthracycline scaffold for designing DNA-targeting agents.
    Priebe W; Fokt I; Przewloka T; Chaires JB; Portugal J; Trent JO
    Methods Enzymol; 2001; 340():529-55. PubMed ID: 11494869
    [No Abstract]   [Full Text] [Related]  

  • 26. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorinated anthracyclines: synthesis and biological activity.
    Tonkin KC; Brownlee RT; Zunino F; Phillips DR
    Invest New Drugs; 1990 Feb; 8(1):1-6. PubMed ID: 2345065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers.
    Mueller BM; Wrasidlo WA; Reisfeld RA
    Bioconjug Chem; 1990; 1(5):325-30. PubMed ID: 1711377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.
    Garrigues J; Anderson J; Hellström KE; Hellström I
    J Cell Biol; 1994 Apr; 125(1):129-42. PubMed ID: 7511141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
    Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
    Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New anthracycline antibiotics 10-epi-oxaunomycin and 10-epi-11-deoxyoxaunomycin.
    Johdo O; Nishida H; Okamoto R; Yoshimoto A; Takeuchi T
    J Antibiot (Tokyo); 1995 Oct; 48(10):1153-8. PubMed ID: 7490224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
    Liu XY; Zhen YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.
    Remsen LG; Trail PA; Hellström I; Hellström KE; Neuwelt EA
    Neurosurgery; 2000 Mar; 46(3):704-9. PubMed ID: 10719867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of monoclonal antibody chimeric BR96-doxorubicin immunoconjugate by sodium dodecyl sulfate-capillary gel electrophoresis with ultraviolet and laser-induced fluorescence detection.
    Liu J; Abid S; Lee MS
    Anal Biochem; 1995 Aug; 229(2):221-8. PubMed ID: 7485976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
    Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
    de Groot FM; de Bart AC; Verheijen JH; Scheeren HW
    J Med Chem; 1999 Dec; 42(25):5277-83. PubMed ID: 10602713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
    J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.